ERBB2 and breast carcinoma: The clinical trial of Slamon DJ et al. evaluated the efficacy and safety of trastuzumab and showed that trastuzumab could significantly improve the symptoms and prolong the OS of HER2-positive advanced breast cancer patients, making trastuzumab + chemotherapy the standard regimen for HER2-positive advanced breast cancer [34].